CRISPR Base Editing Shows Promise in Treating Cystic Fibrosis Mutation
Recent advancements in CRISPR gene editing have demonstrated potential in treating cystic fibrosis, particularly targeting the 1717-1G>A mutation. This mutation, which affects the cystic fibrosis transmembrane conductance regulator (CFTR) protein, has been challenging to treat with existing therapies. Researchers have utilized a base editing strategy, specifically the ABE9 base editor, to correct this mutation in cell models. The study achieved up to 30% editing efficiency in human embryonic kidney cell lines and patient-derived airway epithelial cells, with minimal off-target effects. This approach could benefit patients with severe splicing mutations that result in frameshifts and premature termination codons, who currently have limited treatment options. 
